Affimed Advances in Innate Cell Engager Therapies for Cancer Treatment
Affimed's Innovative Approach to Cancer Treatment
Affimed is at the forefront of developing Innate Cell Engager (ICE®) therapies, focusing on activating the innate immune system to combat cancer. The company's proprietary technology targets CD16A on natural killer (NK) cells and macrophages, enabling a novel approach to cancer treatment that leverages antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Clinical Programs and Efficacy
Affimed has three ongoing clinical programs targeting both solid and hematologic tumors:
-
AFM24: Targeting EGFR in advanced/metastatic non-small cell lung cancer (NSCLC), AFM24 has shown encouraging efficacy in combination with atezolizumab, a checkpoint inhibitor. Clinical trials have demonstrated a 76% disease control rate (DCR) and 48% tumor shrinkage in EGFR wildtype patients.
-
Acimtamig (AFM13): In combination with AlloNK®, AFM13 targets CD30 in relapsed/refractory (R/R) Classical Hodgkin Lymphoma (HL), achieving an 86% overall response rate (ORR) and 55% complete response (CR) rate.
-
AFM28: As a monotherapy for R/R CD123+ acute myeloid leukemia (AML), AFM28 has shown promising activity, with a 40% complete response with incomplete count recovery (CRcR) at the highest dose level.
Safety and Future Directions
All of Affimed's clinical programs have maintained manageable safety profiles, both as monotherapies and in combination with other treatments. The company's innovative approach not only maximizes the activity of innate immune cells but also optimizes the crosstalk between innate and adaptive immune cells, offering a comprehensive strategy to enhance cancer treatment efficacy.
Affimed's leadership team, with extensive experience in life sciences and biotechnology, is steering the company towards further advancements in cancer therapy. With Fast Track and RMAT designations from the FDA, Affimed is well-positioned to expedite the development and approval of its groundbreaking therapies, aiming to address significant unmet needs in cancer treatment.